Comparing of VIVUS Inc. (VVUS) and Celldex Therapeutics Inc. (NASDAQ:CLDX)

We are comparing VIVUS Inc. (NASDAQ:VVUS) and Celldex Therapeutics Inc. (NASDAQ:CLDX) on their institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation. They both are Biotechnology companies, competing one another.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
VIVUS Inc. 3 -1.76 9.75M -3.22 0.00
Celldex Therapeutics Inc. 2 0.00 15.07M -4.54 0.00

Table 1 shows the gross revenue, earnings per share and valuation for VIVUS Inc. and Celldex Therapeutics Inc.


Table 2 has VIVUS Inc. and Celldex Therapeutics Inc.’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
VIVUS Inc. 298,375,003.83% 90.4% -11.4%
Celldex Therapeutics Inc. 634,019,100.51% -40.8% -30.9%

Risk and Volatility

A 1.79 beta means VIVUS Inc.’s volatility is 79.00% more than Standard & Poor’s 500’s volatility. Celldex Therapeutics Inc.’s 3.57 beta is the reason why it is 257.00% more volatile than Standard & Poor’s 500.


VIVUS Inc.’s Current Ratio is 4 while its Quick Ratio is 3.5. On the competitive side is, Celldex Therapeutics Inc. which has a 7.4 Current Ratio and a 7.4 Quick Ratio. Celldex Therapeutics Inc. is better positioned to pay off short and long-term obligations compared to VIVUS Inc.

Institutional and Insider Ownership

Roughly 17.1% of VIVUS Inc. shares are owned by institutional investors while 25.5% of Celldex Therapeutics Inc. are owned by institutional investors. 2.1% are VIVUS Inc.’s share owned by insiders. Competitively, Celldex Therapeutics Inc. has 0.36% of it’s share owned by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
VIVUS Inc. 1.21% -12.79% -9.73% -29.24% -51.56% 49.78%
Celldex Therapeutics Inc. -3.11% -18.96% -41.55% -64.55% -67.34% -26.56%

For the past year VIVUS Inc. has 49.78% stronger performance while Celldex Therapeutics Inc. has -26.56% weaker performance.

VIVUS, Inc., a biopharmaceutical company, develops and commercializes therapies to address unmet medical needs in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or 27 or greater in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction. It is also developing Qsymia, which has completed Phase II studies for the treatment of obstructive sleep apnea and diabetes, as well as for other obesity-related diseases, including nonalcoholic steatohepatitis, nonalcoholic fatty liver disease, hyperlipidemia, and hypertension. In addition, the company is developing Tacrolimus, which has completed Phase IIa studies for the treatment of pulmonary arterial hypertension. It has development, license and clinical trial, and commercial supply agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of avanafil, a PDE5 inhibitor compound for the oral and local treatment of male and female sexual dysfunction. The company also has license and commercialization agreements with Berlin-Chemie AG and Auxilium Pharmaceuticals, Inc. to commercialize and promote STENDRA; and with Sanofi Winthrop Industrie to commercialize and promote avanafil. VIVUS, Inc. was founded in 1991 and is headquartered in Campbell, California.

Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. Its drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; and Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer. It also develops earlier stage drug candidates in clinical development, including CDX-1401, an immunotherapeutic for cancer indications; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor; and CDX-014, an antibody-drug conjugate targeting renal and ovarian cancers. In addition, the company focuses on the discovery and development of antibody-based drugs targeting receptor tyrosine kinases, such as CDX-0158, a humanized monoclonal antibody currently in a Phase 1 dose escalation study in refractory gastrointestinal stromal tumors and other KIT positive tumors; and CDX-3379, a human monoclonal antibody, which has completed a Phase 1b study in patients with solid tumors. Celldex Therapeutics, Inc. has research collaboration and license agreements with Medarex, Inc.; Rockefeller University; University of Southampton; Amgen Inc.; Amgen Fremont; and Seattle Genetics, Inc. The company is headquartered in Hampton, New Jersey.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.